SCHEMBL14616059

SCHEMBL14616059

Cc1cccccn(N)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
ACHE P22303 3/20 0.46
CYP3A4 P08684 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 4/20 0.34
HPGD P15428 4/20 0.34
NPSR1 Q6W5P4 3/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
ATM Q13315 1/20 0.33
KMT2A Q03164 1/20 0.32
CA2 P00918 2/20 0.32
CA1 P00915 1/20 0.32
CA7 P43166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616122 0.79 TSHR (0.46) TSHRACHEALDH1A1HPGDNPSR1
O-Xylene SCHEMBL3640206 0.71 TSHR (0.91) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL11253661 0.71 TSHR (0.91) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL1077768 0.71 TSHR (0.91) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL17318270 0.71 TSHR (0.91) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL27256493 0.68 TSHR (0.83) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL2288470 0.68 TSHR (0.83) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL16537456 0.68 TSHR (0.83) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL21987916 0.68 TSHR (0.83) TSHRACHECYP3A4TDP1ALDH1A1
O-Xylene SCHEMBL10522915 0.67 TSHR (1.00) TSHRACHECYP3A4TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. GHSR, IGF1R, GIPR TSHR 40/4885ACHE 3977/4885CYP3A4 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.